This observational study will evaluate the effectiveness of BRAF inhibitors and current therapies in patients with newly diagnosed metastatic melanoma with or without BRAF V600 mutation. Patients will be treated per the locally approved therapeutic options in clinical practice. The observation period for each patient will be up to 24 months.
Inclusion Criteria:
Exclusion Criteria:
Naples, Campania 80131, Italy
Bologna, Emilia-Romagna 40138, Italy
Meldola, Emilia-Romagna 47014, Italy
Rome, Lazio 00161, Italy
Genoa, Liguria 16132, Italy
Milan, Lombardy 20141, Italy
Florence, Tuscany 50125, Italy
Siena, Tuscany 53100, Italy